text.skipToContent text.skipToNavigation
No se han encontrado resultados
Sugerencias de búsqueda
Familias de Productos
Show all Product Families ()
Artículo
Show all Articles ()
Contenido
Show all Content ()
GMP info

Regarding suitability of Eppendorf bioprocess equipment in GMP-regulated applications, please reach out to your Eppendorf sales representative.

Monoclonal Antibody Process Development

Monoclonal antibody production using scalable bioprocess systems
At Eppendorf, our aim is to empower your monoclonal antibody process development. We provide tools that help you accelerate process development by working in parallel, increasing turn-around, and leveraging the full potential of bioprocess data. We help scaling up your process from R&D to production while maintaining quality and yield. We pay attention to your specific challenges, and we work together with you to solve them. So come and talk to us, we are all ears.
Contact us

Originally, for monoclonal antibody production mAb-producing cells (hybridomas) were generated by fusing immortal myeloma cells with antibody-producing B cells. Today, Chinese Hamster Ovary (CHO) cells are often used as an expression system. Antibody production in bacteria or yeast offers greater speed, however there are challenges associated with glycosylation. Find out more about bioprocessing methods for mAB generation in our ebook!

Download ebook
mab_ebook_730px_x_411px

mAB discovery workflow

Antibody development is not without its challenges. Research teams are under increasing pressure to produce specific, high-quality therapeutic treatments within ever-tighter time and budget restrictions. As such, it is essential to optimize each step of the monoclonal antibody production process, from transfection, to clone selection, to process control and scale-up. From choosing candidate cell lines to scale-up, Eppendorf can help you to maintain a competitive edge by providing the tools, expertise, and knowledge needed to improve and regulate antibody yield and quality.

mAB solutions for biopharma
mAB discovery workflow

Expert knowledge: mAB bioprocess development

Parallel, small-scale bioreactor system, which can help accelerating bioprocess development

Accelerate process development

Learn how the right equipment can accelerate your antibody process development through optimized, real-time parameter control, the ability to set up parallel and scalable reactions, and improved efficiency. With lower development costs and a shorter time for the product to reach the market, your business can stay competitive in an increasingly demanding market.

Learn more
Bioreactor control system, which can help in bioprocess optimization

Improve reproducibility and yield

Antibody production relies upon the interplay of several bioprocess parameters to influence yield and quality. Bioprocess optimization can help to improve reproducibility, reduce batch-to-batch variation, and increase yields and product quality, helping to save time and money in antibody production. This is especially important when seeking to scale up or perform a process validation. Here, we will consider the factors that can contribute to inconsistent results and offer strategies to increase the reproducibility and productivity of cell culture bioprocesses for the production of antibodies.

Learn more

Choose the right bioreactor system for monoclonal antibody process development

Get to know more about cell culture in bioreactors and learn more about the Eppendorf solutions for upstream bioprocessing.

Parallel, small-scale bioprocess systems‌

Single-use bioreactors‌

From small scale to pilot production scale‌

Software‌

How our customers use our products

The real experts are our customers. Meet some of them and find out what their work is all about.
logo_uga_biopharma_730px_x_411px

UGA Biopharma: Scaling-up from small to bench scale

Scaling the process up to larger volumes is a critical milestone in the development of monoclonal antibodies. Read, how scientists at UGA Biopharma scaled-up a biosimilar production process from small to bench scale using the kLa value as a scale-up criterium.

Download application note
1417391_540px_x_304px

KTH Royal Institute of Technology: Small-scale perfusion

Small scale perfusion systems are desired to save resources and reduce costs during process development, however, they are not very well established. Read how researchers at the KTH Royal Institute of Technology in Sweden established ATF perfusion cultivation of an antibody-producing CHO cell line at a working volume of only 230 mL.

Download application note
genmab_video_730px_x_411px

GenMab A/S: Antibody development

Scientists from GenMab A/S, an international biotechnology company specializing in the development of antibody-based therapeutics, were among the first SciVario® twin users. Get to know, which system’s features they find helpful to tackle challenges in antibody development.

Watch video
590688_730px_x_411px

Alvotech®: Bioprocess development for biosimilar production

Bioprocess development for biosimilar production: Scientists from Alvotech® share insights on which process parameters are key to ensure consistent product quality and how automation can make the scientists’ lives easier.

Read interview
145323_730px_x_411px

Roche Pharma Technical Development: Improve pH sensor recalibration

The pH of the culture medium strongly influences process performance. Read, how scientists at Roche Pharma Technical Development used exhaust CO2 readings for improved pH sensor recalibration to match the starting pH of carbonate-buffered systems – for increased process reproducibility cross plants, sites, and scales.

Download application note
logo_apc_730px_x_411px

APC: Raman analyzer integration

Scientists at APC, Ltd integrated a Raman analyzer and a model predictive controller algorithm with a DASGIP® Parallel Bioreactor System. Read, how this allowed them increasing the cell density of their CHO cell bioprocess by automizing glucose control.

Download application note

Eppendorf España

Enlaces rápidos
Soporte
Publicaciones

Suscríbase a nuestro boletín